Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Genetic Signatures Ltd. ( (AU:GSS) ) has provided an announcement.
Genetic Signatures Ltd held its 2025 Annual General Meeting, where resolutions were put to shareholders, resulting in the re-election of directors and approval of remuneration-related resolutions. These outcomes indicate continued support for the company’s leadership and strategic direction, potentially impacting its market positioning and stakeholder confidence positively.
The most recent analyst rating on (AU:GSS) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Genetic Signatures Ltd. stock, see the AU:GSS Stock Forecast page.
More about Genetic Signatures Ltd.
Genetic Signatures Ltd is a molecular diagnostics company specializing in the development and commercialization of its proprietary 3base® platform technology. The company designs and manufactures real-time PCR-based products under the EasyScreen™ brand for the detection of infectious diseases. Its primary market focus is on major hospitals and pathology laboratories for infectious disease screening, leveraging strong sales of its respiratory kits and growing interest in its gastroenteritis products.
Average Trading Volume: 171,728
Technical Sentiment Signal: Sell
Current Market Cap: A$65.87M
Learn more about GSS stock on TipRanks’ Stock Analysis page.